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Molecular Determinants of Magnesium Homeostasis:
Insights from Human Disease
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Department of Physiology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre,
Nijmegen, Netherlands
Magnesium (Mg2) is the second most
common intracellular cation.1 Its abun-
dance facilitates multiple roles that it
plays in common, essential intracellular
processes. It is a co-factor inmultiple en-
zymatic reactions, including those in-
volving energy metabolism and DNA
and protein synthesis, and it participates
in the regulation of ion channels.2 Mg2
homeostasis is therefore fundamental to
the existence of life. Mg2 balance in the
body is controlled by a dynamic interplay
among intestinal absorption, exchange
with bone, and renal excretion.3 This last
process is where the greatest regulation
occurs and consequently is the major fo-
cus of this review.
The consequence of alteredMg2 ho-
meostasis is multifold. Hypermag-
nesemia can cause neurologic and car-
diac sequelae, including lethargy,
confusion, coma, a prolongation in the
PR interval, widened QRS, complete
heart block, and cardiac arrest.4 Hypo-
magnesemia results in similar clinical
manifestations that include tetany, sei-
zures, and cardiac arrhythmias.4,5 Al-
tered plasma Mg2 levels can in turn af-
fect calcium (Ca2) and potassium (K)
levels.4–7 Thus, understandingMg2 ho-
meostasis is important not only for the
treatment of these disorders but also for
the understanding and management of
other electrolyte abnormalities. Al-
though Mg2 homeostasis has been
studied for decades, it is only recently
that the molecular determinants of this
process have become clearer. Much of
this insight derives from the study of pa-
tients, often children, with disorders of
Mg2 wasting. From these studies, the
molecular determinants of Mg2 ho-
meostasis have started to be unraveled.
INTESTINAL UPTAKE
Typically, 300 mg of Mg2 is ingested
daily, 24 to 75% of which is absorbed, a
process dependent on body stores and
dietary content.8–10 The entire length of
the bowel is capable of absorbing Mg2.
As occurs in the nephron, intestinal ab-
sorption proceeds in both a passive para-
cellular and an active transcellular man-
ner.8,11 Mg2 absorption from the small
bowel occurs predominately in a paracel-
lular manner.12,13 Given the appropriate
driving force, significant paracellular ab-
sorption can also take place in the co-
lon.12 The kinetics of this movement are
governed by active absorption of sodium
(Na) followed by water.14 Mg2 and
other ions flow down their concentra-
tion gradient from bowel lumen to peri-
intestinal capillary. It is noteworthy that
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ABSTRACT
The past decade has witnessed multiple advances in our understanding of mag-
nesium (Mg2) homeostasis. The discovery that mutations in claudin-16/paracel-
lin-1 or claudin-19 are responsible for familial hypomagnesemia with hypercalciuria
and nephrocalcinosis provided insight into the molecular mechanisms governing
paracellular transport of Mg2. Our understanding of the transcellular movement
of Mg2was similarly enhanced by the realization that defects in transient receptor
potential melastatin 6 (TRPM6) cause hypomagnesemia with secondary hypocal-
cemia. This channel regulates the apical entry of Mg2 into epithelia. In so doing,
TRPM6 alters whole-body Mg2 homeostasis by controlling urinary excretion.
Consequently, investigation into the regulation of TRPM6 has increased. Acid-base
status, 17 estradiol, and the immunosuppressive agents FK506 and cyclosporine
affect plasma Mg2 levels by altering TRPM6 expression. A mutation in epithelial
growth factor is responsible for isolated autosomal recessive hypomagnesemia,
and epithelial growth factor activates TRPM6. A defect in the -subunit of the
Na,K-ATPase causes isolated dominant hypomagnesemia by altering TRPM6 ac-
tivity through a decrease in the driving force for apical Mg2 influx. We anticipate
that the next decade will provide further detail into the control of the gatekeeper
TRPM6 and, therefore, overall whole-body Mg2 balance.
J Am Soc Nephrol 19: 1451–1458, 2008. doi: 10.1681/ASN.2008010098
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under conditions producing a luminal
driving force, such as diarrheal states,
Mg2 can be secreted into the lumen of
the gut along with water and electro-
lytes.11
Active transcellular absorption of
Mg2 occurs almost exclusively in the
colon.5,8 The rare monogenetic disorder
hypomagnesemia with secondary hy-
pocalcemia (HSH) provides molecular
insight into this process. Children with
this disease have seizures and tetany, sec-
ondary to extremely lowMg2 levels.15,16
Their hypomagnesemia is due to a failure
in the active transcellular (re)absorption
of Mg2 from both the gut and the kid-
ney.17–20 A mutation in the transient re-
ceptor potential (TRP) channel transient
receptor potentialmelastatin 6 (TRPM6)
was found to be responsible for this dis-
ease.21,22 Localization studies demon-
strated this channel in the colon and dis-
tal convoluted tubule (DCT), which is
the site of active renal transcellular reab-
sorption.23,24 At the subcellular level,
TRPM6 is predominantly expressed api-
cally.23Hence, elucidation of this rare ge-
netic disorder resulted in the discovery of
the apical entry mechanism for Mg2
into epithelia. The molecular identity of
the protein responsible for the basolat-
eral exit of Mg2 from the epithelial cell
remains unidentified. Furthermore,
whether there exists an intracellular
chaperone that facilitates transcellular
diffusion of Mg2, as occurs for Ca2, is
also not known.
BONE: A MG2 RESERVOIR
The majority of the body’s Mg2
(50%) resides within the skeleton, as
part of the hydroxyapatite crystalline
structure.1,9,25 As is the case for Ca2,
bone is thought to provide a buffer for
plasma Mg2, leaching Mg2 when
plasma levels drop and facilitating the
synthesis of new bone when the circulat-
ing level is plentiful.26 Consistent with
this notion, animals fed Mg2-deficient
diets have a bone Mg2 content that is
reduced by 30 to 40% and a reduced
bone mineral density.27–29 This is medi-
ated by a decrease in the number of os-
teoblasts, with inhibited function,9,27,28
and an increase in both the number and
function of osteoclasts.9,27–29 Finally,
current data, although by nomeans con-
clusive, suggest that Mg2 deficiency
predisposes an individual to osteoporo-
sis.29–32 Unfortunately, our understand-
ing of the molecular details governing
the incorporation of Mg2 into bone by
osteoblasts and its retrieval by osteoclasts
is minimal.
RENAL REGULATION OF MG2
EXCRETION
Approximately 80% of total plasma
Mg2 is filtered by the glomeruli,33,34 the
vast majority of which is absorbed along
the course of the nephron.6 On a normal
diet, fractional excretion of Mg2 is be-
tween 3 and 5%35; however, in the pres-
ence of hypomagnesemia, this can be de-
creased to 0.5 to 1% to conserve Mg2
stores.36 The majority of filtered Mg2 is
absorbed in the proximal tubule (ap-
proximately 20%) and thick ascending
limb (TAL) of the loop of Henle (ap-
proximately 70%) by a passive paracellu-
lar mechanism (Figure 1).37,38 That two
thirds of filteredMg2 is absorbed in the
TAL and not the proximal tubule is
unique for renal tubular ion transport.
All ions studied to date, except forMg2,
are reabsorbed to a greater extent in the
proximal tubule. The remaining 10% of
filtered Mg2 is absorbed by an active
transcellular mechanism in DCT.6 This
latter process ultimately controls the
amount of Mg2 excreted in the urine,
because no Mg2 reabsorption occurs
distal to this segment.6 TheDCT is there-
fore the predominant site of specifically
regulatedMg2 excretion. Insights gleaned
from the delineation of monogenetic
Mg2 wasting disorders have proved
highly valuable in deciphering the mo-
lecular events governing renal regulated
excretion (Figure 1, Table 1).39,40
Paracellular Transport: The
Proximal Tubule and Loop of Henle
Reabsorption of Mg2 from the lumen
of the proximal tubule andTALoccurs in
a passive, paracellular manner.38 Mg2
flows between the epithelial cells down
its electrochemical gradient.39 The exact
determinants that govern paracellular
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Figure 1. Renal regulation of Mg2 ho-
meostasis. A total of 80% of Mg2 is fil-
tered at the glomeruli, 15% of which is
absorbed proximally, 70% in the TAL, and
15% in the DCT, leaving 3 to 5% to be
excreted in the urine. The TAL is the main
site of passive paracellular reabsorption of
Mg2, a process mediated by claudin-16
and -19. This paracellular reabsorption de-
pends on the active reabsorption of Na,
which is mediated by apical entry through
sodium potassium chloride cotransporter
(NKCC) and efflux via the Na,K-ATPase.
Efflux of chloride (Cl) occurs through
CLCKb, and K is recycled back into the
lumen via ROMK. The Ca2-sensing receptor (CaSR) acts to inhibit this process and prevent both paracellular Ca2 and Mg2
reabsorption. In the DCT, luminal Mg2 enters via TRPM6. The mediator of its efflux is unknown. Intracellular Mg2 and RACK1 inhibit
TRPM6. EGF, cleaved from the basolateral membrane, activates TRPM6, and its expression is increased by estradiol. EGFR, EGF
receptor; PT, proximal tubule.
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Mg2 movement are, as yet, unknown.
Surprising, whereas 60% of filtered
Na and water is absorbed in the proxi-
mal tubule, only approximately 15% of
Mg2 is reabsorbed in this segment.37,38
This is in direct contrast toCa2, another
divalent cation reabsorbed by the para-
cellular route, which is absorbed in a
similar ratio to Na and water.40 The
majority ofMg2 is absorbed in the TAL,
approximately 70%.39 This observation
suggests that something facilitates para-
cellularMg2 absorption in the TAL that
is absent in the proximal tubule.37
It was through study of a rare disor-
der of Mg2 wasting, familial hypo-
magnesemia with hypercalciuria and
nephrocalcinosis (FHHNC), that the
molecular identity of this paracellular
mediator was identified. Patients with
FHHNC havemutations in claudin-16/
paracellin-1,41–44 a protein localized
exclusively to the tight junction of epi-
thelia in the TAL.43,44 Claudins are tet-
raspanning, transmembrane proteins
localized to the tight junction by zona
occludens proteins.45,46 Their localiza-
tion and both intracellular and inter-
cellular interactions are postulated to
form pores that regulate paracellular
movement of ions.47,48 Absent or faulty
claudin-16 activity could therefore
prevent the reabsorption of Mg2 (as
well as Ca2) and result in FHHNC.
Consistent with this hypothesis is the
recent observation that a similar phe-
notype is observed in individuals with
mutations in claudin-19, which is also
located at the tight junction of the
TAL.49,50 That claudin-16 affects para-
cellular permeability is supported by
heterologous expression studies dem-
onstrating increased paracellular flux
of cations.51,52 A recent study extended
this observation to demonstrate a func-
tional interaction between claudin-16
and -19 in renal epithelia at the tight
junction, which increases cation selec-
tivity above that of claudin-16 in isola-
tion.53
Amolecular enigma is presented by the
most common monogenetic disorder re-
sulting in Mg2 wasting, Gitelman syn-
drome. Patients with this disorder have a
mutation in the thiazide-sensitive Na/
Cl co-transporter (NCC).54,55 Their dis-
ease is characterized by a hypokalemic
metabolic alkalosis with hypomagnesemia
and hypocalciuria.56 Inhibition of NCC
with thiazide diuretics results in a similar
phenotype.57 Mice genetically engineered
with null alleles of the gene encodingNCC
or those treated with thiazide diuretics
have decreased expression of TRPM6.58
This channel is the protein responsible for
apical entry of luminalMg2 and provides
an explanation for the Mg2 wasting ob-
served in this disease23; however what sig-
nals the decrease in abundance of TRPM6
in the absence of NCC activity is unclear.
Transcellular Transport: The DCT
The DCT is the last site of Mg2 reab-
sorption in the nephron and the only site
where it occurs in an active transcellular
manner.6 There has been significant re-
cent progress in understanding the mo-
lecular details governing this process.
Study of the affected protein, TRPM6, in
patients withHSH reveals its localization
to the DCT.23 Moreover, Mg2 loading
experiments demonstrated that these in-
dividuals not only failed to absorb Mg2
from the gut but also had a renal leak.17
As with intestinal epithelia, subcellular
localization of TRPM6 in DCT is apical,
supporting a role for this channel in lu-
minal Mg2 influx.23 In parallel to the
gut, the mechanism of basolateral efflux
of Mg2 is unknown, although it is spec-
ulated this occurs through exchangewith
Na in a secondarily active process (Fig-
ure 1).59 Because the apical membrane
potential in the DCT is approximately
70 mV or greater,60,61 the Nernst po-
tential favors Mg2 influx. In fact, be-
cause intracellular and extracellular
Mg2 concentrations are compara-
ble,62,63 membrane potential is likely the
major determinant of apical Mg2 en-
try.26 Consequently, energy must be ex-
pended to effect its efflux at the basolat-
eral membrane.6 As such, it is possible
that Mg2 efflux is mediated by an ATP-
dependent Mg2 pump.6
It is unclear whether intracellular
Mg2 is buffered by a chaperone in the
kidney; if so, then the identity of such a
chaperone is also a matter of specula-
tion.64 In DCT, parvalbumin and, to a
lesser extent, calbindin-D28K have over-
Table 1. Proteins implicated in the molecular control of Mg2 homeostasisa
Protein Gene Localization Function
Associated Human
Disease
Reference
Claudin-16/
paracellin-1
CLDN16 TAL, tight junction Permissive of paracellular
permeability
FHHNC 41–44,53
Claudin-19 CLDN19 TAL, tight junction Permissive of paracellular
permeability
FHHNC 49,50,53
NCC SLC12A3 DCT, apical membrane Sodium chloride co-transporter Gitelman syndrome 54,55
TRPM6 TRPM6 DCT, apical membrane, colon, lung Selective Mg2 channel, apical
entry in transcellular
transport
HSH 17–23
Na,K-ATPase
-subunit
FXYD2 PT, MD/DCT, ?TAL, medulla Alters kinetics of Na and K
exchange
Isolated dominant
hypomagnesemia
76–80,82
EGF EGF Adrenal, brain, heart, kidney (DCT),
salivary gland, spleen, thymus,
intestine, thyroid, and uterus
Increases TRPM6 activity Isolated recessive
hypomagnesemia
87
aThe gene name, renal localization, function, and associated human disease of proteins known to be involved in the molecular control of Mg2 homeostasis.
PT, proximal tubule.
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lapping expression with TRPM6.23,65
Both proteins have an affinity for Mg2
that favors binding under physiologic
conditions.66 Recently, investigators
made a parvalbumin null mouse.65 The
null animal has polydipsia and polyuria
as a result of a decrease in NCC expres-
sion. Ca2 excretion is somehow de-
creased, whereas renal Mg2 excretion is
unaltered, neither confirming nor ex-
cluding parvalbumin from a role in DCT
Mg2 reabsorption. Whether these ani-
mals will inappropriately excrete Mg2
when deprived remains unclear. Regard-
less, intracellular concentrations of
Mg2 in the millimolar range are not
detrimental to a cell (as would be the case
for Ca2), and, unlike Ca2 that is used
as a dynamic signaling molecule, the in-
tracellular concentration of Mg2 is not
known to fluctuate. This obviates the ne-
cessity for a Mg2 chaperone; however
such a chaperonemay increase the rate at
which Mg2 can diffuse from the apical
to basolateral cell surface. Alternatively,
because intracellular Mg2 is known to
inhibit TRPM6,23 such a chaperone
would relieve the Mg2-dependent inhi-
bition of TRPM6. Both of these possibil-
ities would increase the efficiency of
transcellular Mg2 transport. This op-
tion remains speculative, and further re-
search will elucidate whether this mech-
anism exists in vivo.
TRPM6
TRPM6 has only recently been confirmed
as thechannel responsible for theapical en-
try of Mg2 into epithelia; consequently,
the amount of information with respect to
its regulation is limited (Table 2). Its loca-
tion and function position it to be a key
modulator of Mg2 homeostasis. As such,
this is anareaof active researchwith several
recent, interesting results.
Structure of TRPM6
TRPM6 is predicted to share structural
homology to other TRP channels. It is
composed of a large intracellular amino-
terminus, six membrane-spanning do-
mains that make up the channel pore,
and a large intracellular carboxy-termi-
nal domain. Fused to the carboxy-termi-
nus is an -kinase domain.67 The func-
tional unit is thought to be a homo- or
heterotetramer with TRPM7.68,69 The
exact composition is debated in the liter-
ature. We have been able to express
TRPM6 successfully in mammalian cells
and characterize the electrophysiologic
properties of the channel without coex-
pressing TRPM7.23 Consistent with this,
Li et al.68 detected TRPM6-specific cur-
rents from the plasmamembrane of cells
in the presence and absence of TRPM7.
Furthermore, two separate studies dem-
onstrated by heterologous expression
(without coexpressingTRPM7) thatmu-
tation of a single residue (E1024) in the
pore region ofTRPM6 alters cation selec-
tivity of the channel70,71 and its sensitiv-
ity to extracellular pH.71 Together, these
studies suggested that TRPM6 can func-
tion as a homotetramer. This is in con-
trast to findings in Xenopus oocytes and
in inducible mammalian cell culture sys-
tems, where coexpression of TRPM7 is
required for plasma membrane localiza-
tion and TRPM6-specific currents.69,72,73
These authors used electrochemical, bio-
chemical, and immunofluorescent tech-
niques to show that a direct interaction
between TRPM6 and TRPM7 is required
for plasma membrane localization of
TRPM6.69,72,73What the actual composi-
tion of the functional unit of channels is
in native epithelia remains unclear.
Function of TRPM6
TRPM6 and TRPM7 are unique chan-
nels. They conduct Mg2 preferentially
over Ca223,68 and contain a functional
-kinase domain. This has dubbed them
chanzymes.67 The-kinase domain plays
a role in regulating channel activity. This
domain is not necessary for basal func-
tion; however, as with TRPM7, auto-
phosphorylation is amechanism regulat-
ing channel activity.74,75 TRPM6 is a
cation-selective channel with strong out-
ward rectification. It is inhibited by ru-
thenium red in a voltage-dependent
manner, and intracellular Mg2 acts as a
negative regulator of channel activity.23
Furthermore, an acidic extracellular pH
inhibits the conductance of TRPM6, a
characteristic dependent on specific res-
idues in the pore region.71 Together these
properties provide a means to regulate
the apical entry of Mg2 from tubular
fluid and ultimately regulate whole-body
Mg2 homeostasis.
Recently, a new TRPM6-interacting
protein, receptor for activated C-ki-
nase 1 (RACK1), has been described.75
This protein interacts directly with the
-kinase domain inhibiting channel
Table 2. Effectors of Mg2 homeostasisa
Effector Effect on TRPM6 Effect on Mg2 Homeostasis Reference
EGF 1 Activity, mechanism unknown Hypomagnesuria (hypermagnesemia) 87–89
RACK1 1 Activity, via association and
phosphorylation of the  kinase domain
nd 75
Mg2 (intracellular) 2 Activity 1 Urinary Mg2 excretion 23,24
Mg2 (extracellular) 2 TRPM6 expression 1 Urinary Mg2 excretion 24
Acidosis 2 TRPM6 expression/2 activity 1 Urinary Mg2 excretion (hypomagnesemia) 71,94
Alkalosis 1 TRPM6 expression 2 Urinary Mg2 excretion (hypermagnesemia) 94
17-estradiol 1 TRPM6 expression 2 Urinary Mg2 excretion 24
FK506/cyclosporine 2 TRPM6 expression 1 Urinary Mg2 excretion (hypomagnesemia) 95,96
Thiazide diuretic 2 TRPM6 expression 1 Urinary Mg2 excretion (hypomagnesemia) 58
aThe known effectors of TRPM6 and their effect on TRPM6 activity and the mechanism (if known) and their affect on magnesium (Mg2) homeostasis.
nd, not determined.
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activity. The interaction itself is inde-
pendent of the phosphorylation state
of the kinase domain; however,
RACK1-mediated inhibition requires
autophosphorylation of residue T1851
in the kinase domain.75 Furthermore,
the inhibition of TRPM6 activity by in-
tracellular Mg2 depends on this auto-
phosphorylation. It is possible, there-
fore, that TRPM6-mediated Mg2
influx induces phosphorylation of
T1851 located in the -kinase domain,
a process that activates the inhibitory
effect of RACK1. This last step may act
as an intracellular feedbackmechanism
controlling TRPM6-mediated Mg2
influx and preventing Mg2 overload
during renal epithelial Mg2 transport.
The notion that transcellular Mg2
transport, specificallyMg2 flux through
TRPM6, is dependent on membrane po-
tential is supported by the finding that a
defect in the -subunit of the Na,K-AT-
Pase causes isolated dominant hypomag-
nesemia.76 The exact location of this kid-
ney-specific subunit of the Na,K-ATPase
is debated, although it has been localized
to the same part of the nephron as
TRPM6, the DCT,77–80 as well as the re-
nal medulla.81 The null mouse has nearly
a 50% increase in Mg2 excretion,78 and
although not significantly different from
wild-type mice, it certainly suggests a
role for this protein in renal Mg2 han-
dling. Expressionwith the other subunits
alters the kinetics of the pump such that
it has an increased affinity for K at neg-
ative membrane potentials,77,82 a de-
creased affinity for Na,77,83 and altered
affinity for ATP.84 Coexpression of the
mutant subunit with wild-type protein
prevented trafficking to the plasma
membrane,76,85 although association be-
tween wild-type and mutant subunits is
not observed with synthetic peptides.86
Regardless, decreased or absent -sub-
units affect pump activity and conse-
quently alter intracellular K concentra-
tion. This could, in turn, inhibit
transcellular transport of Mg2 because
of an altered membrane potential. The
exact mechanism causing increased uri-
nary Mg2 excretion and hypomag-
nesemia has yet to be determined but is
an area of active research.
Local Regulation of TRPM6
Recently, the identification of the caus-
ative mechanism for another Mg2-
wasting disease, isolated autosomal re-
cessive hypomagnesemia (IRH),
provided further insight into the regula-
tion of TRPM6 and identified the first
magnesiotropic hormone.87 A family
with hypomagnesemia was found to
have amutation in the gene encoding ep-
ithelial growth factor (EGF) that is ex-
pressed in DCT along with TRPM6. The
mutation was in the cytosolic carboxy-
terminus, within a conserved basolat-
eral-sortingmotif (PXXP), prompting us
to suggest that trafficking to the basolat-
eral membrane and consequent release
into the extracellular space are inhibited.
Consistent with our hypothesis, the ap-
plication of EGF to cells expressing
TRPM6 increased the activity of this
channel. Furthermore, when cultureme-
dium from cells expressing wild-type
EGF was applied to TRPM6, channel ac-
tivity increased, whereas medium from
cells expressing mutant EGF did not
stimulate TRPM6.87 Several other obser-
vations support a role for EGF in regulat-
ing TRPM6 activity. Lactating ewes,
when administered EGF, have a decrease
in fractional excretion of Mg2 and de-
velophypermagnesemia.88 Patients treated
with the anticancer agent cetuximab, a
mAb that blocks the EGF receptor, de-
velop hypomagnesemia secondary to in-
creased renal wasting.89 Taken together,
these findings suggest that renal EGF acts
in an autocrine or a paracrine manner to
increase TRPM6 activity. This stimulates
the reabsorption ofMg2 fromDCT and
consequently decreases the fractional ex-
cretion of Mg2 (Figure 1).90
Systemic Regulation of TRPM6
Reduction in dietary Mg2 results in hy-
pomagnesemia. This in turn stimulates
Mg2 reabsorption along the DCT.35,91
Rodents fed a diet deficient in Mg2
demonstrated an increase in colonic, ce-
cal, and DCT expression of TRPM6.24
Coincident with this increase in TRPM6,
their urinary excretion of Mg2 (and
Ca2) diminished. Conversely, animals
fed a diet high inMg2 paradoxically up-
regulated colonic TRPM6 yet remained
eumagnesemic secondary to an in-
creased renal excretion of Mg2.24
17-Estradiol also increased the ex-
pression of TRPM6.24 Indeed, ovariecto-
mized rats showed a decrease in levels of
TRPM6 (and magnesuria) that was nor-
malized by administration of the hor-
mone.24 This is in contrast to vitamin D
and parathyroid hormone, which are un-
able to alter TRPM6 expression in vivo;
however, they both increased Mg2 in-
flux in a DCT cell culture model as mea-
sured by radiometric imaging using
Mag-fura.3,6 These results can be recon-
ciled as an effect mediated by altered ac-
tivity, not by expression level of the chan-
nel. Given the presumed clarity of these
later studies characterizing the affect of
hormones on Mg2 influx in cell culture
and the availablemicropuncture andmi-
croperfusion data,6,92 it is likely that our
understanding of the hormonal regula-
tion of TRPM6 activity will grow even
further.
The acid-base status of an individual
affects the body’s handling of Mg2.92,93
This occurs through an alteration in lev-
els of TRPM6. Mice with chronic meta-
bolic acidosis display a reduced renal ex-
pression of TRPM6, increased excretion
of Mg2, and decreased plasma Mg2,94
whereasmetabolic alkalosis results in the
opposite effect.94 Finally, long-term ad-
ministration of the immunosuppressive
agent FK506 commonly causes hypo-
magnesemia. Both this compound and
cyclosporine mediate this effect by de-
creasing the expression of TRPM6, ex-
plaining this common clinical complica-
tion of kidney transplantation.95,96
CONCLUSIONS
Studies on monogenetic disorders of
Mg2wasting have unraveled themolec-
ular details of renal and intestinal Mg2
absorption and consequently whole-
body Mg2 homeostasis. Renal paracel-
lular transport of Mg2 in the TAL oc-
curs in the presence of claudin-16/19,
and loss of functioning claudin-16/19
causes FHHNC as a result of Mg2wast-
ing. Gitelman syndrome, a disease char-
acterized by renal salt loss because of a
BRIEF REVIEWwww.jasn.org
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defect in NCC, results in hypokalemic
metabolic alkalosis and hypomag-
nesemia. The exact mechanism of this
latter finding remains unknown; how-
ever, absent or inhibited NCC activity
leads to the downregulation of TRPM6,
the DCT channel responsible for apical
entry of Mg2. This channel plays a cen-
tral role inMg2 homeostasis by regulat-
ing the luminal entry ofMg2 in both the
DCT and the intestine. The absence or
malfunction of TRPM6 results in severe
hypomagnesemia and is responsible for
HSH. TRPM6 is regulated at the tran-
scriptional level by acid-base status, 17-
estradiol, and both FK506 and cyclo-
sporine. We are just beginning to
understand how its activity is regulated
in a shorter time scale through traffick-
ing to the plasma membrane or from al-
terations in channel kinetics. To this end,
both EGF and RACK1 are implicated in
its acute regulation. Indeed,mutations in
the former protein have been found to
cause IRH.
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